Equities research analysts expect Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to announce $68.62 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Supernus Pharmaceuticals’ earnings, with the highest sales estimate coming in at $71.62 million and the lowest estimate coming in at $65.99 million. Supernus Pharmaceuticals reported sales of $50.42 million during the same quarter last year, which indicates a positive year-over-year growth rate of 36.1%. The company is scheduled to announce its next earnings results on Tuesday, August 1st.

According to Zacks, analysts expect that Supernus Pharmaceuticals will report full year sales of $68.62 million for the current financial year, with estimates ranging from $280.18 million to $287.29 million. For the next fiscal year, analysts anticipate that the business will report sales of $371.54 million per share, with estimates ranging from $354.32 million to $384.63 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $0.19 EPS for the quarter, missing analysts’ consensus estimates of $0.22 by $0.03. Supernus Pharmaceuticals had a return on equity of 31.79% and a net margin of 42.46%. The company had revenue of $57.58 million for the quarter, compared to analyst estimates of $57.91 million.

SUPN has been the subject of a number of recent analyst reports. Cantor Fitzgerald reiterated a “buy” rating and set a $31.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, March 1st. Jefferies Group LLC restated a “buy” rating and issued a $33.00 target price on shares of Supernus Pharmaceuticals in a research note on Thursday, March 2nd. Zacks Investment Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 4th. Stifel Nicolaus raised their target price on Supernus Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, April 3rd. Finally, Cowen and Company raised their target price on Supernus Pharmaceuticals from $31.00 to $34.00 and gave the company an “outperform” rating in a research note on Thursday, May 11th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $33.43.

ILLEGAL ACTIVITY WARNING: “Supernus Pharmaceuticals, Inc. (SUPN) Expected to Announce Quarterly Sales of $68.62 Million” was published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/06/23/supernus-pharmaceuticals-inc-supn-expected-to-announce-quarterly-sales-of-68-62-million.html.

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 11,806 shares of Supernus Pharmaceuticals stock in a transaction dated Monday, April 24th. The stock was sold at an average price of $32.59, for a total transaction of $384,757.54. Following the completion of the transaction, the vice president now owns 45,500 shares in the company, valued at approximately $1,482,845. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Gregory S. Patrick sold 54,000 shares of Supernus Pharmaceuticals stock in a transaction dated Monday, April 24th. The shares were sold at an average price of $32.37, for a total value of $1,747,980.00. Following the transaction, the chief financial officer now owns 54,221 shares of the company’s stock, valued at approximately $1,755,133.77. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 83,806 shares of company stock valued at $2,813,038. 6.70% of the stock is currently owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in SUPN. Juncture Wealth Strategies LLC increased its position in Supernus Pharmaceuticals by 0.8% in the first quarter. Juncture Wealth Strategies LLC now owns 51,459 shares of the specialty pharmaceutical company’s stock worth $1,611,000 after buying an additional 433 shares during the period. Dimensional Fund Advisors LP increased its position in Supernus Pharmaceuticals by 4.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,107,007 shares of the specialty pharmaceutical company’s stock worth $27,952,000 after buying an additional 51,511 shares during the period. Virginia Retirement Systems ET AL increased its position in Supernus Pharmaceuticals by 17.1% in the first quarter. Virginia Retirement Systems ET AL now owns 71,800 shares of the specialty pharmaceutical company’s stock worth $2,247,000 after buying an additional 10,500 shares during the period. New York State Teachers Retirement System increased its position in Supernus Pharmaceuticals by 0.5% in the fourth quarter. New York State Teachers Retirement System now owns 77,035 shares of the specialty pharmaceutical company’s stock worth $1,945,000 after buying an additional 400 shares during the period. Finally, Comerica Bank increased its position in Supernus Pharmaceuticals by 5.5% in the fourth quarter. Comerica Bank now owns 52,831 shares of the specialty pharmaceutical company’s stock worth $1,326,000 after buying an additional 2,771 shares during the period. Institutional investors and hedge funds own 92.08% of the company’s stock.

Shares of Supernus Pharmaceuticals (SUPN) traded up 1.83% during midday trading on Friday, hitting $44.45. The company had a trading volume of 296,549 shares. Supernus Pharmaceuticals has a one year low of $17.25 and a one year high of $44.95. The stock’s 50-day moving average price is $35.99 and its 200-day moving average price is $29.53. The stock has a market capitalization of $2.24 billion, a price-to-earnings ratio of 23.91 and a beta of 1.76.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.